Amphista Therapeutics
PrivateLast Round
Series B
Extension
Dec 13, 2022
Total Funding Raised
$60.5M
Momentum Score
25 /100
Company Overview
Amphista Therapeutics is a biotechnology company focused on developing next-generation targeted protein degradation therapeutics and technologies aimed at treating various diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amphista Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Amphista Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 13, 2022 | ||||
| Series B | Mar 17, 2021 | ||||
| Series A | Apr 7, 2020 | ||||
| Seed | Dec 20, 2017 |
Key People
Founding team and executive leadership
Amphista Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| BioMotiv | Series B, Series A |
| Advent Life Sciences | Series B, Seed, Series B Extension, Series A |
| European Investment Fund | Seed, Series A |
| Gilde Healthcare | Series B |
| Novartis Venture Fund | Series B |
| Scottish Investment Bank (Scottish Enterprise) | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Three presentations scheduled at the AACR 2026 Annual meeting.
- Mar 23, 2026
Launched SMARCA2 degraders for NSCLC treatment.
Amphista Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amphista Therapeutics's valuation, stock price, and market status.
